• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»depression treatment

Diamond Lake Clinic’s EXOMIND rollout signals shifting priorities in noninvasive depression treatment

By Pallavi Madhiraju on February 14, 2026   Medical Devices & Diagnostics  

Diamond Lake Clinic’s EXOMIND rollout signals shifting priorities in noninvasive depression treatment

Diamond Lake Clinic introduces EXOMIND for depression care. Find out what this shift means for neuromodulation, evidence standards, and mental health treatment models.

Can ketamine treatment clinics like Serenity redefine psychiatric care delivery in suburban America?

By Pallavi Madhiraju on January 20, 2026   Pharma & Biotech  

Can ketamine treatment clinics like Serenity redefine psychiatric care delivery in suburban America?

Serenity expands ketamine therapy in Florida. Find out how this signals a shift in psychiatric care access and what clinicians are watching next.

Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression

By Pallavi Madhiraju on January 17, 2026   Pharma & Biotech  

Elunetirom shows synaptogenic promise as Autobahn eyes pivotal trials in depression

Autobahn’s elunetirom may offer a novel neuroplasticity-driven treatment for depression. Find out what its latest data mean for the future of MDD therapy.

Recent Posts

  • Could KARL STORZ’s Rubina Lens turn open surgery into the next imaging battleground?
  • Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?
  • Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window
  • Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing
  • Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy
  • Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test
  • Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis
  • Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets
  • Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets
  • Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?
  • Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics
  • Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes